- Home
- BLTE vs MAC Comparison
BLTE vs MAC Comparison
Compare BLTE & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLTE | MAC |
|---|---|---|
| Founded | 2018 | 1964 |
| Country | United States | United States |
| Employees | N/A | 2845 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.2B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BLTE | MAC |
|---|---|---|
| Price | $154.79 | $25.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $198.00 | $20.50 |
| AVG Volume (30 Days) | 146.1K | ★ 2.0M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | N/A | ★ 11.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,013,983,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $492.11 | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.43 |
| 52 Week Low | $60.00 | $16.03 |
| 52 Week High | $200.00 | $26.68 |
Technical Indicators
Market Signals| Indicator | BLTE | MAC |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 56.45 |
| Support Level | $145.11 | $24.97 |
| Resistance Level | $160.72 | $25.97 |
| Average True Range (ATR) | 6.09 | 0.61 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 52.71 | 53.08 |
Price Performance
Historical ComparisonAbout BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.2 million square feet of gross leasable area and averaged $899 sales per square foot over the 12 months ended in March 2026.